Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of four randomized controlled trials

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 12, 2011, Pages 1785-1790

  Qi, Wei Xiang ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Castration resistant prostate cancer; Docetaxel; Estramustine; Meta analysis

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; NAVELBINE; PROSTATE SPECIFIC ANTIGEN;

ANEMIA; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; UNITED STATES; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; MALE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 82955161684     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1052-7     Document Type: Article

References (18)

1. CB Begg M Mazumdar 1994 Operating characteristics of a rank correlation test for publication bias Biometrics 50 1088 1101 7786990 10.2307/2533446 1:STN:280:DyaK2Mzgs1GrtQ%3D%3D
2. DL Berry CM Moinpour CS Jiang, et al. 2006 Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone J Clin Oncol 24 2828 2835 16782921 10.1200/JCO.2005.04.8207 1:CAS:528: DC%2BD28XntV2gsr0%3D (Pubitemid 46630582)
3. O Caffo T Sava E Comploj, et al. 2008 Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial BJU Int 102 1080 1085 18485028 10.1111/j.1464-410X.2008.07779.x 1:CAS:528: DC%2BD1cXhsFSjs7bK
4. JC Eymard F Priou A Zannetti, et al. 2007 Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer Ann Oncol 18 1064 1070 17434899 10.1093/annonc/mdm083 (Pubitemid 47050499)
5. K Fizazi A Le Maitre G Hudes, et al. 2007 Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data Lancet Oncol 8 994 1000 17942366 10.1016/S1470-2045(07)70284-X 1:CAS:528:DC%2BD2sXht1GrsbnN (Pubitemid 47629887)
6. PO Gunnarsson GP Forshell 1984 Clinical pharmacokinetics of estramustine phosphate Urology 23 6 Suppl 22 27 6375076 10.1016/S0090-4295(84)80093-X 1:STN:280:DyaL2c3isFClug%3D%3D
7. NM Hahn S Marsh W Fisher, et al. 2006 Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis Clin Cancer Res 12 6094 6099 17062685 10.1158/1078-0432.CCR-06-1188 1:CAS:528:DC%2BD28XhtFWhsbnJ (Pubitemid 44703774)
8. A Hamilton F Muggia 2001 Estramustine potentiates taxane in prostate and refractory breast cancers Oncology 15 5 Suppl 7 40 43 11396364 1:STN:280:DC%2BD3MzivVOmtQ%3D%3D (Pubitemid 33739140)
9. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
10. JP Machiels F Mazzeo M Clausse, et al. 2008 Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer J Clin Oncol 26 5261 5268 18794543 10.1200/JCO.2008.16.9524 1:CAS:528:DC%2BD1cXhsVyqsrbI
11. S Oudard ME Legrier K Boye, et al. 2003 Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts J Urol 169 1729 1734 12686819 10.1097/01.ju.0000062500.75703.2c 1:CAS:528:DC%2BD3sXislGqurk%3D (Pubitemid 36443482)
12. MK Parmar V Torri L Stewart 1998 Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 2815 2834 9921604 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID- SIM110>3.0.CO;2-8 1:STN:280:DyaK1M7itVWksA%3D%3D (Pubitemid 28562978)
13. CM Perry D McTavish 1995 Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer Drugs Aging 7 49 74 7579781 10.2165/00002512-199507010-00006 1:STN:280:DyaK28%2FovF2guw%3D%3D
14. DP Petrylak CM Tangen MH Hussain, et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520 15470214 10.1056/NEJMoa041318 1:CAS:528:DC%2BD2cXot1Kmu7c%3D (Pubitemid 39315318)
15. IF Tannock R de Wit WR Berry, et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512 15470213 10.1056/NEJMoa040720 1:CAS:528:DC%2BD2cXot1Kmu7s%3D (Pubitemid 39315317)
16. JF Williams HJ Muenchen JM Kamradt, et al. 2000 Treatment of androgen-independent prostate cancer using anti-microtubule agents docetaxel and estramustine in combination: an experimental study Prostate 44 275 278 10951491 10.1002/1097-0045(20000901)44:4<275::AID-PROS3>3.0.CO;2-9 1:CAS:528:DC%2BD3cXmsF2gsbs%3D
17. S Yusuf R Peto DR Jones, et al. 1985 Beta blockade during and after myocardial infarction: an overview of the randomized trials Prog Cardiovasc Dis 27 335 371 2858114 10.1016/S0033-0620(85)80003-7 1:STN:280:DyaL2M7ktFSitw%3D%3D (Pubitemid 15107153)
18. E Zintzaras JP Ioannidis 2005 Heterogeneity testing in meta-analysis of genome searches Genet Epidemiol 28 123 137 15593093 10.1002/gepi.20048